Korea Investment Partners
Korea Investment Partners is a prominent venture capital and private equity firm based in Seoul, South Korea, with over 30 years of experience in the investment sector. Founded in 1986, the firm focuses on supporting bold and innovative entrepreneurs across various industries, including biotechnology, healthcare, interactive content, media, consumer internet, financial technology, information and communication technology, digitalization, semiconductor, and industrial sectors. Korea Investment Partners has established a strong track record by investing in notable companies such as Kakao, Naver, YG Entertainment, Bodyfriend, and Didi Chuxing. The firm manages more than 20 venture and private equity funds, with total assets under management amounting to approximately $1.8 billion. In addition to its headquarters in Seoul, Korea Investment Partners has offices in Shanghai, Beijing, and Sunnyvale, allowing it to operate on a global scale.
Past deals in Dietary Supplements
My Herb & Healthcare
Series A in 2025
MyHerb Healthcare proivdes a specialized analysis for nutritional supplements.
Brave Company
Series A in 2024
Brave Company is a wellness enterprise that develops and markets consumer health brands, focusing on convenient, nutritious products like chicken breast and diet foods. Their mission is to transform daily health habits by integrating their offerings into everyday routines, such as exercise, meals, and social activities. They achieve this by supporting and collaborating with creators through a platform that provides brand incubation, marketing support, personalized recommendations, performance analytics, and offline fitness facilities.
Dr.Diary
Series B in 2022
Dr.Diary is a company that specializes in developing a diabetes management application aimed at assisting users in monitoring and controlling their diabetes. Founded in 2017 and headquartered in Seoul, South Korea, the application allows users to track their blood glucose levels, record daily exercise routines, and receive reminders for medication intake. Additionally, it offers insights into how various foods affect blood sugar levels, thereby helping users make informed dietary choices. The platform includes features such as monthly health reports, daily tips for diabetes management, and communication tools that facilitate personal consultations with healthcare professionals. Through these services, Dr.Diary aims to empower individuals with diabetes to better manage their health and improve their quality of life.
Genome
Series B in 2018
Genome & Company, headquartered in Seongnam, South Korea, specializes in researching microbes and probiotics to develop dietary supplements, cosmeceuticals, and novel drugs targeting conditions such as obesity, diabetes, acne, atopic dermatitis, and cancer-related therapies.
Genome
Series A in 2017
Genome & Company, headquartered in Seongnam, South Korea, specializes in researching microbes and probiotics to develop dietary supplements, cosmeceuticals, and novel drugs targeting conditions such as obesity, diabetes, acne, atopic dermatitis, and cancer-related therapies.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.